What are the causes of low lymphocytes in MS?

Hi,

Welcome to icliniq.com.

I have read your query and can understand your concern.

Mavenclad (Cladribine) is a disease-modifying therapy for multiple sclerosis (MS) that selectively depletes lymphocytes, a type of white blood cell crucial for immune response. While effective in controlling MS, it can also suppress the immune system, increasing the risk of infections when lymphocyte levels fall significantly.

Lymphocyte counts typically range from 1.0 to 3.0 x 10⁹/L. A count of 0.3 x 10⁹/L is considered severely low, indicating significant immune suppression. When lymphocyte levels drop this low, the body’s ability to fight infections is compromised, leading to an increased risk of viral, bacterial, and fungal infections.

Although lymphopenia is expected with Mavenclad due to its mechanism of action, recurrent infections are concerning. The key challenge is balancing MS management with infection risk. If her lymphocyte count remains critically low for too long or if infections become severe or frequent, the risks of continuing treatment may outweigh the benefits.

Should treatment be paused?

This decision should involve both her neurologist and primary care physician, ensuring a coordinated approach. Key considerations include:

1. Assessing her infection risk: If her infections are mild and manageable, treatment may continue with close monitoring. However, severe or frequent infections may warrant temporarily pausing Mavenclad to allow immune recovery.

2. Monitoring her lymphocyte count: Her doctor may recommend periodic blood tests to track recovery. If her lymphocyte count improves, treatment may resume safely.

3. Prophylactic measures: Some physicians prescribe vaccinations, antibiotics, or antifungal medications to reduce infection risk while on Mavenclad. Discuss with her doctor whether any additional precautions are necessary.

4. Considering alternative therapies: If the risks of continued use are too high, her healthcare team may explore alternative MS treatments with a more favorable safety profile, depending on her MS severity and available options.

Given the severity of her lymphopenia and recurrent infections, prompt action is necessary. A frank discussion with her healthcare team about risk vs. benefit is essential to ensure her immune system remains protected while maintaining effective MS management. Close monitoring and collaboration between her neurologist and primary care physician will help determine the best course of action for her overall health.

I hope this information helps.

Thank you.